Journal
JOURNAL OF CHEMOTHERAPY
Volume 34, Issue 3, Pages 184-189Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/1120009X.2021.1959787
Keywords
Everolimus; exemestane; endocrine therapy; endocrine resistance; breast cancer; interstitial pneumonitis
Ask authors/readers for more resources
The combination therapy of exemestane and everolimus demonstrates significant efficacy and comparable safety to clinical trials in real-world settings for breast cancer patients.
Everolimus combined with exemestane can modulate endocrine resistance. The combination showed significant improvement in progression-free survival (PFS) in phase III clinical trials for hormone receptor positive metastatic breast cancer patients. It also showed serious adverse events. We evaluate the efficacy and prevalence of serious adverse events in a real-world setting. We retrospectively examined 91 breast cancer patients; all were previously treated with chemotherapy and fulvestrant (84% and 59%, respectively). After a 13-month median follow-up, 29% had a partial response, and 32% had stable disease. The PFS was 7.8 months. Due to adverse events, 19% of patients stopped the treatment, while 31% required a dose reduction. Despite enrolling heavier-pretreated patients, our real-world outcome for the efficacy and safety of the exemestane and everolimus match those of the clinical trials. Such results should assure clinicians and lead to wider adoption of this oral, chemotherapy-sparing regimen.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available